Medpace (NASDAQ:MEDP) CEO Sells $13,639,455.07 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,883 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $623.29, for a total transaction of $13,639,455.07. Following the transaction, the chief executive officer owned 482,390 shares of the company’s stock, valued at $300,668,863.10. The trade was a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Medpace Trading Down 0.3%

Shares of MEDP stock opened at $618.88 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm’s fifty day moving average price is $594.65 and its two-hundred day moving average price is $515.99. The firm has a market capitalization of $17.27 billion, a P/E ratio of 36.28, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Medpace in the second quarter valued at about $1,323,047,000. Wasatch Advisors LP increased its holdings in shares of Medpace by 19.4% during the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after purchasing an additional 125,625 shares during the period. State Street Corp raised its holdings in Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after acquiring an additional 28,666 shares in the last quarter. Geode Capital Management LLC raised its stake in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after buying an additional 38,760 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MEDP. Robert W. Baird boosted their price target on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Truist Financial raised their target price on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $595.20.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.